REG - Proteome Sciences - Notice of Results

Proteome SciencesAnnouncement

30/03/2020 07:00

For best results when printing this announcement, please click on link below:
http://pdf.reuters.com/htmlnews/htmlnews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20200330:nRSd9632Ha

RNS Number : 9632H  Proteome Sciences PLC  30 March 2020

 
30 March 2020

 

 

Proteome Sciences plc

("Proteome Sciences" or the "Company")

 

Notice of Results

 

Further to our announced intention to publish our audited 2019 full year
results on 31 March 2020, the Board wishes to notify shareholders that this
will now be postponed until Tuesday April 14(th). This follows advice and
additional guidance on financial reporting from the Financial Conduct
Authority and the Financial Reporting Council in light of the ongoing
coronavirus pandemic. Accordingly, the date of the Annual General Meeting
("AGM") will also be revised. We will provide further notification regarding
the date of the AGM as soon as we can be certain of our ability to provide a
safe environment for all wishing to attend.

Despite the ongoing restrictions on non-essential travel and gatherings, both
our UK and German organisations are able to function normally, and we do not
expect the coronavirus pandemic to have a material effect on our first quarter
revenues. The current COVID-19 crisis underlines the necessity for increased
testing and vaccine development in the rapidly changing medical environment.
Several scientific articles are appearing where researchers are using TMT®
proteomics to look at how the virus interacts with the human cellular
proteome, which plays to our core strength.

 

For further information please contact:

 Proteome Sciences plc
 Dr Ian Pike, Interim Chief Executive Officer  Tel: +44 (0)20 7043 2116

 Richard Dennis, Chief Commercial Officer

 Allenby Capital Limited (AIM Nominated Adviser & Broker)
 John Depasquale / Jeremy Porter               Tel: +44 (0) 20 3328 5656

About Proteome Sciences plc. (www.proteomics.com (http://www.proteomics.com/)
)

Proteome Sciences plc is a specialist provider of contract proteomics services
to enable drug discovery, development and biomarker identification, and
employs proprietary workflows for the optimum analysis of tissues, cells and
body fluids.  SysQuant® and TMT®MS2 are unbiased methods for identifying
and contextualising new targets and defining mechanisms of biological
activity, while analysis using Super-Depletion and TMTcalibrator™ provides
access to over 8,500 circulating plasma proteins for the discovery of
disease-related biomarkers. Targeted assay development using mass spectrometry
delivers high sensitivity, interference-free biomarker analyses in situations
where standard ELISA assays are not available.

The Company has its headquarters in London, UK, with laboratory facilities in
Frankfurt, Germany.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.   END  NORFFFFFVAIAFII